ReviewMolecular therapy : the journal of the American Society of Gene Therapy2013
Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Acute Coronary Syndrome in Intensive Care Unit Patients: Troponin or Triglyceride Glucose Index Levels?Journal of clinical medicine · 2025Article
- Beyond Glycemic Control: Vascular Biologic Effects of Antidiabetic Drugs and Their Cardiovascular Promise.Reviews in cardiovascular medicine · 2025Article
- N-Oxalylglycine-Conjugated Hyaluronic Acid as a Macromolecular Prodrug for Therapeutic Angiogenesis.Gels (Basel, Switzerland) · 2025Article
- The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction.Nature reviews. Cardiology · 2024Review
- Direct cardiac reprogramming: A new technology for cardiac repair.Journal of molecular and cellular cardiology · 2023Review
- Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Increased estimated remnant-like particle cholesterol is associated with impaired coronary collateralization in patients with coronary chronic total occlusions.Diabetology & metabolic syndrome · 2022Article
- Fibrin-based factor delivery for therapeutic angiogenesis: friend or foe?Cell and tissue research · 2022Review
- Serum CTRP9 Reflects Coronary Collateralization in Nondiabetic Patients with Obstructive Coronary Artery Disease.BioMed research international · 2022Article
- Association between the triglyceride glucose index and coronary collateralization in coronary artery disease patients with chronic total occlusion lesions.Lipids in health and disease · 2021Observational
- Dach1 Extends Artery Networks and Protects Against Cardiac Injury.Circulation research · 2021Article
- Consideration of clinical translation of cardiac AAV gene therapy.Cell & gene therapy insights · 2020Article
- SLC35E3 identified as a target of novel‑m1061‑5p via microRNA profiling of patients with cardiovascular disease.Molecular medicine reports · 2018Article
- Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Novel molecular targets for coronary angiogenesis and ischemic heart disease.Coronary artery disease · 2017Review
- Coronary Artery Development: Progenitor Cells and Differentiation Pathways.Annual review of physiology · 2017Review
- Genetic lineage tracing discloses arteriogenesis as the main mechanism for collateral growth in the mouse heart.Cardiovascular research · 2016Article
- Adipokine Imbalance in the Pericardial Cavity of Cardiac and Vascular Disease Patients.PloS one · 2016Article
- Reduced Plasma miR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease.BioMed research international · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stimulation of collateral vessel development in the heart by angiogenic growth factor therapy has been tested in animals and humans for almost two decades. Discordance between the outcome of preclinical studies and clinical trials pointed to the difficulties of translation from animal models to patients. Lessons learned in this process identified specific mechanistic, technical, and clinical hurdles, which need to be overcome. This review summarizes current understanding of the mechanisms leading to the establishment of a functional coronary collateral network and the biological processes growth factor therapies should stimulate even under conditions of impaired natural adaptive vascular response. Vector delivery methods are recommended to maximize angiogenic gene therapy efficiency and reduce side effects. Optimization of clinical trial design should include the choice of clinical end points which provide mechanistic proof-of-concept and also reflect clinical benefits (e.g., surrogates to assess increased collateral flow reserve, such as myocardial perfusion imaging). Guidelines are proposed to select patients who may respond to the therapy with high(er) probability. Both short and longer term strategies are outlined which may help to make therapeutic angiogenesis (TA) work in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.